These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37736358)

  • 1. Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)-A review of the evidence.
    Sukkari MH; Al-Bast B; Al Tamimi R; Giesing W; Siddique M
    Am J Prev Cardiol; 2023 Sep; 15():100579. PubMed ID: 37736358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a).
    Razavi AC; Richardson LC; Coronado F; Dzaye O; Bhatia HS; Mehta A; Quyyumi AA; Vaccarino V; Budoff MJ; Nasir K; Tsimikas S; Whelton SP; Blaha MJ; Blumenthal RS; Sperling LS
    Am J Prev Cardiol; 2024 Jun; 18():100674. PubMed ID: 38741703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Ajufo E; Ayers CR; Vigen R; Joshi PH; Rohatgi A; de Lemos JA; Khera A
    JAMA Cardiol; 2021 Feb; 6(2):179-187. PubMed ID: 33112372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease.
    Verweij SL; de Ronde MWJ; Verbeek R; Boekholdt SM; Planken RN; Stroes ESG; Pinto-Sietsma SJ
    J Clin Lipidol; 2018; 12(3):597-603.e1. PubMed ID: 29550494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.
    Al-Sofiani ME; Derenbecker R; Quartuccio M; Kalyani RR
    Curr Diab Rep; 2019 Sep; 19(10):107. PubMed ID: 31544224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events.
    Calderone D; Ingala S; Mauro MS; Angiolillo DJ; Capodanno D
    Expert Rev Cardiovasc Ther; 2021 Dec; 19(12):1097-1117. PubMed ID: 34915778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention.
    Desai D; Ahmed HM; Michos ED
    Curr Cardiol Rep; 2015 Mar; 17(3):566. PubMed ID: 25676828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Plasma Lipoprotein(a) Level and Atherosclerotic Cardiovascular Disease Risks: A Large Clinical Retrospective Study.
    Wang K; Wang W; Niu J; Liu X; Han H; Shen H; Sun Y; Gao W; Ge H
    Angiology; 2024 Mar; ():33197241239688. PubMed ID: 38480469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary use of coronary artery calcium for the allocation of aspirin in light of the 2022 USPSTF guideline recommendations.
    Verghese D; Manubolu S; Budoff MJ
    Am J Prev Cardiol; 2022 Dec; 12():100427. PubMed ID: 36407963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
    J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin and lipoprotein(a) in primary prevention.
    Bhatia HS
    Curr Opin Lipidol; 2023 Oct; 34(5):214-220. PubMed ID: 37527183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
    Fonseca AF; Byrne H; Laguna A; Itani T; Studer R; Heo J; Dillon A; Ferber P; Costa-Scharplatz M
    J Manag Care Spec Pharm; 2023 May; 29(5):519-529. PubMed ID: 37121256
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis.
    Nudy M; Cooper J; Ghahramani M; Ruzieh M; Mandrola J; Foy AJ
    Am J Med; 2020 Sep; 133(9):1056-1064. PubMed ID: 32445718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
    Cainzos-Achirica M; Miedema MD; McEvoy JW; Al Rifai M; Greenland P; Dardari Z; Budoff M; Blumenthal RS; Yeboah J; Duprez DA; Mortensen MB; Dzaye O; Hong J; Nasir K; Blaha MJ
    Circulation; 2020 May; 141(19):1541-1553. PubMed ID: 32233663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
    Makover ME; Shapiro MD; Toth PP
    Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk.
    Mehta A; Virani SS; Ayers CR; Sun W; Hoogeveen RC; Rohatgi A; Berry JD; Joshi PH; Ballantyne CM; Khera A
    J Am Coll Cardiol; 2020 Aug; 76(7):781-793. PubMed ID: 32792075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
    Mufarreh A; Shah AJ; Vaccarino V; Kulshreshtha A
    JAMA Netw Open; 2023 Jan; 6(1):e2251156. PubMed ID: 36656581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and Increased Cardiovascular Risk in Women.
    Costello BT; Silverman ER; Doukky R; Braun LT; Aggarwal NT; Deng Y; Li Y; Lundberg G; Williams KA; Volgman AS
    Clin Cardiol; 2016 Feb; 39(2):96-102. PubMed ID: 26880352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.